- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03772002
Hepatitis C Surveillance With Linkage to Care of Patients From Non-ID Departments in Jiangsu
Hepatitis C Surveillance With Linkage to Care of Patients From Non-infectious Departments in Tertiary Hospitals From Jiangsu, China
Due to the occult nature of hepatitis C virus (HCV), it is estimated that less than 5% of people with chronic hepatitis C (CHC) infection knowing their status. The major challenges are that awareness is lacking, reliable diagnostics and testing services are not sufficiently available, and laboratory capacity is weak. In the context of major tertiary hospitals, the well-functioning laboratories would ensure the high-quality HCV testing, which facilitate the identification of inpatients who are unaware of HCV infection. However, given the preliminary data, diagnostic rate of inpatients from non-infectious (non-ID) departments is disturbingly low. A recent study from a major hospital in Jilin province of China showed that 3.36% of inpatients were anti-HCV positive; however, HCV RNA confirmatory testing was not further performed in this study.
From the retrospective cohort in non-ID departments of a tertiary hospital of Jiangsu during 2016 to 2017, only 25.9% (71/273) of patients with anti-HCV antibody (Ab) further had HCV RNA confirmatory test, while 40% (29/71) were identified as CHC. The previous data indicates that insufficient anti-HCV Ab testing and insufficient follow-up of patients with positive anti-HCV Ab from non-ID departments. Indeed, compared to hospitals in Western countries, the infectious department in Chinese hospitals are relative independent from non-ID departments, meanwhile the knowledge of HCV infection is relatively lacking for non-ID physicians. Therefore, an appropriate clinical pathway for integration and linkage of non-ID department and ID departments for diagnosis and care delivery of CHC patients is urgently needed. The investigator aim to establish a feasible clinical pathway and consensus guideline to enhance HCV testing surveillance with linkage to care in non-ID departments. Moreover, the participants with anti-HCV Ab also will be enrolled in the HCV prospective cohort, in which the intervention and clinical outcome of hepatitis will be longitudinally monitored in the future study.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Förväntat)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Jiangsu
-
Changzhou, Jiangsu, Kina, 213001
- The Third Hospital of Changzhou
-
Nanjing, Jiangsu, Kina, 210008
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Retrospective cohort:
- ≥ 18 years of age.
- Inpatients from non-infectious department.
- Documentation of laboratory test indicating positive HCV antibody.
Prospective cohort:
- ≥ 18 years of age.
- Inpatients from non-infectious departments.
Patients who meet the requirement of HCV antibody screening:
- patients with high risk possibility of HCV infection.
- patients who will have special or invasive medical operation.
- patients with unexplained abnormal liver biochemical laboratory results.
Exclusion Criteria:
Retrospective cohort: Duplicated subjects.
Prospective cohort:Inability or unwillingness to provide informed consent or abide by the requirements of the study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Undersökning
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: HCV screening
|
HCV antibody and HCV RNA surveillance, anti-HCV treatment assessment
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
The percentage of patients in non-infectious departments who had positive HCV antibody testing but failed to get HCV RNA test.
Tidsram: 1 years
|
1 years
|
The percentage of HCV-RNA positivity among patients with the presence of anti-HCV antibody in non-infectious departments after Non-ID HCV screening.
Tidsram: 1 years
|
1 years
|
The percentage of HCV-RNA positivity linkage to care consensus guideline shaped.
Tidsram: 1 years
|
1 years
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
The percentage of CHC patients linked to care in non-infectious departments.
Tidsram: 1 years
|
1 years
|
The treatment timeliness as embodied as time period from diagnosis to engagement to anti-HCV DAA treatment.
Tidsram: 1 years
|
1 years
|
The referral rate of identified HCV infected patients.
Tidsram: 1 years
|
1 years
|
Samarbetspartners och utredare
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Förväntat)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- IN-CN-987-5343
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Hepatit C, kronisk
-
Clínica de Oftalmología de Cali S.AAvslutadMeibomisk körteldysfunktion | Eyes Dry ChronicColombia
-
Alcon ResearchAvslutad
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekryteringRefractory Chronic Graft Versus Host Disease (cGVHD)Belgien
-
Dhulikhel HospitalKathmandu University School of Medical SciencesIndragenPostoperativ analgesi | CSOM - Chronic Suppurative Otitis MediaNepal
-
Dokuz Eylul UniversityEge UniversityAvslutadMMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/CKalkon
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsIndragenKronisk hepatit C-virusinfektionIsrael
-
Hadassah Medical OrganizationOkändKronisk hepatit C-virusinfektionIsrael
-
Tripep ABInovio PharmaceuticalsOkändKronisk hepatit C-virusinfektionSverige
-
Trek Therapeutics, PBCAvslutadKronisk hepatit C | Hepatit C genotyp 1 | Hepatit C (HCV) | Hepatit C virusinfektionFörenta staterna, Nya Zeeland
-
Trek Therapeutics, PBCAvslutadKronisk hepatit C | Hepatit C (HCV) | Hepatit C genotyp 4 | Hepatit C virusinfektionFörenta staterna
Kliniska prövningar på HCV screening
-
University of La LagunaRekrytering
-
University of La LagunaAvslutadHepatit C-virusinfektionSpanien
-
Denver Health and Hospital AuthorityBoston University; Johns Hopkins University; Boston Medical Center; University... och andra samarbetspartnersAktiv, inte rekryterande
-
New York City Health and Hospitals CorporationAvslutadHepatit C | HIV/AIDS | Hiv | HCV saminfektion | HIV/AIDS och infektionerFörenta staterna
-
ANRS, Emerging Infectious DiseasesAvslutadDrog användning | HCV-infektionFrankrike
-
Centre hospitalier de l'Université de Montréal...Merck Sharp & Dohme LLC; Gilead Sciences; Ministere de la Sante et des Services...Avslutad
-
Hasselt UniversityOkändHepatit C | Drog användningBelgien
-
Hospital Universitario Infanta LeonorFundacion SEIMC-GESIDA; Instituto de Salud Carlos IIIAvslutadHepatit C | HIV | Skademinskning | Narkotikaanvändare
-
University of New MexicoAvslutad
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; Fondation... och andra samarbetspartnersOkänd